Literature DB >> 26503884

Therapy: Avoiding treatment failures associated with HCV resistance.

Jean-Michel Pawlotsky1.   

Abstract

Mesh：

Year:  2015        PMID： 26503884     DOI： 10.1038/nrgastro.2015.184

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  8 in total

1.  EASL Recommendations on Treatment of Hepatitis C 2015.

Authors: 
Journal:  J Hepatol       Date:  2015-04-21       Impact factor: 25.083

Review 2.  Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus.

Authors: 
Journal:  Hepatology       Date:  2015-08-04       Impact factor: 17.425

Review 3.  Hepatitis C treatment: the data flood goes on-an update from the liver meeting 2014.

Authors:  Jean-Michel Pawlotsky
Journal:  Gastroenterology       Date:  2015-01-07       Impact factor: 22.682

Review 4.  New hepatitis C therapies: the toolbox, strategies, and challenges.

Authors:  Jean-Michel Pawlotsky
Journal:  Gastroenterology       Date:  2014-03-12       Impact factor: 22.682

5.  Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection.

Authors:  Jean-Michel Pawlotsky; Robert Flisiak; Shiv K Sarin; Jens Rasenack; Teerha Piratvisuth; Wan-Long Chuang; Cheng-Yuan Peng; Graham R Foster; Samir Shah; Heiner Wedemeyer; Christophe Hézode; Wei Zhang; Kelly A Wong; Bin Li; Claudio Avila; Nikolai V Naoumov
Journal:  Hepatology       Date:  2015-08-10       Impact factor: 17.425

6.  The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus.

Authors:  Robert Flisiak; Andrzej Horban; Philippe Gallay; Michael Bobardt; Suganya Selvarajah; Alicja Wiercinska-Drapalo; Ewa Siwak; Iwona Cielniak; Jozef Higersberger; Jarek Kierkus; Christian Aeschlimann; Pierre Grosgurin; Valérie Nicolas-Métral; Jean-Maurice Dumont; Hervé Porchet; Raf Crabbé; Pietro Scalfaro
Journal:  Hepatology       Date:  2008-03       Impact factor: 17.425

7.  Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial.

Authors:  Stefan Zeuzem; Reem Ghalib; K Rajender Reddy; Paul J Pockros; Ziv Ben Ari; Yue Zhao; Deborah D Brown; Shuyan Wan; Mark J DiNubile; Bach-Yen Nguyen; Michael N Robertson; Janice Wahl; Eliav Barr; Joan R Butterton
Journal:  Ann Intern Med       Date:  2015-07-07       Impact factor: 51.598

8.  Targeting a host-cell entry factor barricades antiviral-resistant HCV variants from on-therapy breakthrough in human-liver mice.

Authors:  Koen Vercauteren; Richard J P Brown; Ahmed Atef Mesalam; Juliane Doerrbecker; Sabin Bhuju; Robert Geffers; Naomi Van Den Eede; C Patrick McClure; Fulvia Troise; Lieven Verhoye; Thomas Baumert; Ali Farhoudi; Riccardo Cortese; Jonathan K Ball; Geert Leroux-Roels; Thomas Pietschmann; Alfredo Nicosia; Philip Meuleman
Journal:  Gut       Date:  2015-08-25       Impact factor: 23.059
  8 in total
  7 in total

Review 1.  Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals.

Authors:  Asma Ahmed; Daniel J Felmlee
Journal:  Viruses       Date:  2015-12-18       Impact factor: 5.048

2.  Characterization of the Anti-HCV Activities of the New Cyclophilin Inhibitor STG-175.

Authors:  Philippe A Gallay; Udayan Chatterji; Michael D Bobardt; Zhengyu Long; Shengli Zhang; Zhuang Su
Journal:  PLoS One       Date:  2016-04-22       Impact factor: 3.240

Review 3.  Hepatitis C virus management: potential impact of nanotechnology.

Authors:  Mostafa H Elberry; Noureldien H E Darwish; Shaker A Mousa
Journal:  Virol J       Date:  2017-05-02       Impact factor: 4.099

4.  High resolution sequencing of hepatitis C virus reveals limited intra-hepatic compartmentalization in end-stage liver disease.

Authors:  Ditte L Hedegaard; Damien C Tully; Ian A Rowe; Gary M Reynolds; David J Bean; Ke Hu; Christopher Davis; Annika Wilhelm; Colin B Ogilvie; Karen A Power; Alexander W Tarr; Deirdre Kelly; Todd M Allen; Peter Balfe; Jane A McKeating
Journal:  J Hepatol       Date:  2016-08-13       Impact factor: 25.083

5.  Glecaprevir/pibrentasvir+sofosbuvir: an optimal retreatment strategy in the setting of HCV NS5A resistance.

Authors:  Arshia Alimohammadi; Brian Conway; Leo Yamamoto
Journal:  BMJ Case Rep       Date:  2020-02-11

6.  Cyclophilin Inhibitors Remodel the Endoplasmic Reticulum of HCV-Infected Cells in a Unique Pattern Rendering Cells Impervious to a Reinfection.

Authors:  Udayan Chatterji; Michael Bobardt; Lana Schaffer; Malcolm Wood; Philippe A Gallay
Journal:  PLoS One       Date:  2016-07-21       Impact factor: 3.240

7.  Adaptive mutation F772S-enhanced p7-NS4A cooperation facilitates the assembly and release of hepatitis C virus and is associated with lipid droplet enlargement.

Authors:  Xiaobing Duan; Muhammad Ikram Anwar; Zhanxue Xu; Ling Ma; Guosheng Yuan; Yiyi Chen; Xi Liu; Jinyu Xia; Yuanping Zhou; Yi-Ping Li
Journal:  Emerg Microbes Infect       Date:  2018-08-08       Impact factor: 7.163
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.